Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions

Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals, is unveiling the Signals Clinical™ solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics.

Seres’ microbiome therapy reduces infections in stem cell transplant patients, but next steps are unclear

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 13, 2024

Bayer details data from two Phase 3 trial wins for menopause symptom drug

Bayer shared more data on its menopause symptom drug elinzanetant, which demonstrates how the treatment triumphed over placebo in two of three Phase 3 trials.

May 18, 2024

GSK secures another ex-China ADC deal with Hansoh Pharma with $185M upfront

The year of antibody-drug conjugates isn’t done yet, as GSK is adding another licensing partnership with Hansoh Pharma for another ADC with an upfront payment

December 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.